LAVA Therapeutics to Participate at the UBS Global Healthcare Conference
May 05 2022 - 7:00AM
LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company
focused on developing its proprietary Gammabody™ platform of
bispecific gamma delta T cell engagers to transform the treatment
of cancer, today announced that Stephen Hurly, president and chief
executive officer of LAVA Therapeutics, will participate in a
fireside chat at the UBS Global Healthcare Conference 2022 being
held in New York, NY.
Presentation DetailsFormat: Fireside chat Date: Monday, May 23,
2022Time: 4:15-4:45p.m. ET.
A live webcast of the fireside chat and a replay of the fireside
chat can be accessed under the "Events" tab on the investor
relations section of the LAVA Therapeutics website at:
https://ir.lavatherapeutics.com/news-events/events.
About LAVA TherapeuticsLAVA Therapeutics N.V.
is an immuno-oncology company utilizing its proprietary Gammabody™
platform to develop a portfolio of bispecific gamma delta T
cell engagers for the potential treatment of solid and
hematological malignancies. The Company utilizes bispecific
antibodies engineered to selectively kill cancer cells by
triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell antitumor effector
functions upon cross-linking to tumor associated antigens.
LAVA-051, the Company’s lead candidate for the treatment of
multiple myeloma, chronic lymphocytic leukemia and acute myeloid
leukemia, is enrolling patients in a Phase 1/2a clinical study
(NCT04887259). A Phase 1/2a clinical study to evaluate LAVA-1207 in
patients with metastatic castration-resistant prostate cancer
(mCRPC) is also enrolling. For more information, please
visit www.lavatherapeutics.com, and follow us
on LinkedIn, Twitter and YouTube.
CONTACTSEdward SmithChief Financial
Officerir@lavatherapeutics.com
Argot Partners (IR/Media)212-600-1902lava@argotpartners.com
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Apr 2023 to Apr 2024